Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
Denali Therapeutics Q1 Financial Results Analysis
2d ago
seekingalpha
Privium Fund Management Acquires Stake in Denali Therapeutics
4d ago
Fool
Transformation of Value in Biotechnology Sector
Apr 20 2026
Globenewswire
Biotechnology Sector Undergoes Value Transformation
Apr 20 2026
Newsfilter
Denali Regains Full Rights to DNL593 Therapy
Apr 06 2026
NASDAQ.COM
Denali Continues Clinical Development of DNL593 After Takeda Collaboration Termination
Apr 03 2026
Newsfilter
Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593
Apr 03 2026
moomoo
Avaí Bio Initiates Master Cell Bank Manufacturing
Apr 01 2026
Newsfilter
Avaí Bio Initiates Master Cell Bank Manufacturing
Apr 01 2026
PRnewswire
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah
Mar 26 2026
Newsfilter
Denali Receives FDA Accelerated Approval for AVLAYAH
Mar 26 2026
NASDAQ.COM
FDA Approves First Treatment for Hunter Syndrome in Nearly 20 Years
Mar 25 2026
Newsfilter
Denali Therapeutics Receives FDA Approval for Avlayah™ (Tividenofusp Alfa-Eknm) to Treat Hunter Syndrome (MPS II)
Mar 25 2026
moomoo
Denali Therapeutics Receives FDA Approval for New Drug
Mar 25 2026
seekingalpha
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
Mar 24 2026
PRnewswire
Show More News
